Literature DB >> 8093631

The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine.

J C Chen1, E R Smith, M Cahill, R Cohen, J B Fishman.   

Abstract

The ability of morphine, fentanyl, butorphanol, nalbuphine, and dezocine to compete with radiolabeled ligands for binding at the mu1, mu2, kappa1, and delta opioid receptors and the sigma receptor was characterized. In the absence of sodium, the potency of opioid receptor competition at each receptor site was found to be: mu1-fentanyl > butorphanol > morphine > or = dezocine = nalbuphine; mu2-butorphanol > fentanyl > nalbuphine > morphine = dezocine; kappa1-butorphanol > nalbuphine >> morphine > or = dezocine > fentanyl; and delta-butorphanol > nalbuphine > or = dezocine > morphine > fentanyl. For all five compounds, competition at the sigma receptor was weak, with nalbuphine and dezocine having Kis of approximately 0.5 microM and the other opioids having Kis of greater than 1 microM. Since the presence of 100 mM NaCl during the competitive binding decreased the K(i), to varying degrees, of all five opioids at the mu1 and delta receptors and of some of the opioids at the mu2 and kappa1 receptors, the five compounds studied appear to differ in efficacy at the five receptor sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093631     DOI: 10.1016/0024-3205(93)90152-s

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  42 in total

1.  Interactions between opioids and cocaine on locomotor activity in rats: influence of an opioid's relative efficacy at the mu receptor.

Authors:  Mark A Smith; Keith A Gordon; Christopher K Craig; Paul A Bryant; M Eric Ferguson; Adam M French; Jason D Gray; Jacob M McClean; Jonathan C Tetirick
Journal:  Psychopharmacology (Berl)       Date:  2003-04-01       Impact factor: 4.530

2.  A multicenter randomized double-blind prospective study of the postoperative patient controlled intravenous analgesia effects of dezocine in elderly patients.

Authors:  Chunying Wang; Lizhi Li; Boxiong Shen; Hui Jiang; Lan Yuan; Dongping Shi; Junfeng Zhu; Xuan Guo; Hua Li
Journal:  Int J Clin Exp Med       Date:  2014-03-15

3.  Acute morphine affects the rat circadian clock via rhythms of phosphorylated ERK1/2 and GSK3β kinases and Per1 expression in the rat suprachiasmatic nucleus.

Authors:  Dominika Pačesová; Barbora Volfová; Kateřina Červená; Lucie Hejnová; Jiří Novotný; Zdeňka Bendová
Journal:  Br J Pharmacol       Date:  2015-05-11       Impact factor: 8.739

4.  Structure Elucidation of Urinary Metabolites of Fentanyl and Five Fentanyl Analogs using LC-QTOF-MS, Hepatocyte Incubations and Synthesized Reference Standards.

Authors:  Jakob Wallgren; Svante Vikingsson; Tobias Rautio; Enas Nasr; Anna Åstrand; Shimpei Watanabe; Robert Kronstrand; Henrik Gréen; Johan Dahlén; Xiongyu Wu; Peter Konradsson
Journal:  J Anal Toxicol       Date:  2021-01-21       Impact factor: 3.367

5.  Prostatic relaxation induced by loperamide is mediated through activation of opioid μ-2 receptors in vitro.

Authors:  Chih-Cheng Lu; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

Review 6.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

7.  Affinity of fentanyl and its derivatives for the σ1-receptor.

Authors:  Piotr F J Lipiński; Edina Szűcs; Małgorzata Jarończyk; Piotr Kosson; Sándor Benyhe; Aleksandra Misicka; Ján Cz Dobrowolski; Joanna Sadlej
Journal:  Medchemcomm       Date:  2019-06-13       Impact factor: 3.597

8.  Repeated restraint stress reduces opioid receptor binding in different rat CNS structures.

Authors:  Giovana Dantas; Iraci Lucena Da Silva Torres; Leonardo Machado Crema; Diogo R Lara; Carla Dalmaz
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

9.  Placebo and Active Treatment Additivity in Placebo Analgesia: Research to Date and Future Directions.

Authors:  Matthew J Coleshill; Louise Sharpe; Luana Colloca; Robert Zachariae; Ben Colagiuri
Journal:  Int Rev Neurobiol       Date:  2018-08-06       Impact factor: 3.230

Review 10.  Transnasal butorphanol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management.

Authors:  J C Gillis; P Benfield; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.